Immatics N.V. (IMTX) Form 6-K — Oct 23, 2026
Immatics announced updated Phase 1 data for IMA203CD8, its PRAME-directed TCR T-cell therapy, in 98 heavily pretreated patients with PRAME-positive solid tumors (data cutoff August 7, 2026). Across 90 efficacy-evaluable patients, the one-time infusion achieved a 51% objective response rate and 41% confirmed ORR, with tumor reduction in 83% of patients and responses ongoing beyond 2.5 years. In gynecologic cancers at clinically relevant doses, ORR was 60% with a median duration of response of 8.4 months and median overall survival not reached.
Key figures
- Orr
- 51% (46/90)
- Data cutoff
- August 7, 2026
- Gyn onc dcr
- 70% (14/20)
- Confirmed orr
- 41% (36/87)
- Median pfs gyn
- 5.8 months
- Safety population
- 98
- Tumor reduction rate
- 83% (71/86)
- Median prior lines all
- 3
- Gyn onc cor at dl4c plus
- 55% (11/20)
- Gyn onc orr at dl4c plus
- 60% (12/20)
- Disease control rate week6
- 82% (74/90)
- Efficacy evaluable patients
- 90
- Median overall survival gyn
- not reached at 7.8 months median follow-up
- Median duration of response gyn
- 8.4 months
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.